| Old Articles: <Older 6351-6360 Newer> |
|---|
 |
BusinessWeek
May 27, 2010
Michelle Cortez |
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug.   |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
May 27, 2010
Brian Orelli |
This Rabid Agency Could Permanently Damage Your Portfolio The FDA has gotten a little out of control. The wonkiness of the FDA's actions makes it hard for investors to figure out what the agency will do. |
The Motley Fool
May 27, 2010
Brian Orelli |
Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve. |
The Motley Fool
May 27, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Brigantine recommends purchase of Kinetic Concepts in the medical products arena. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme. |
The Motley Fool
May 25, 2010
Brian Orelli |
Medtronic Gets Tossed Out With the Bathwater A bad day to report good news. |
The Motley Fool
May 24, 2010
Brian Orelli |
ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse. |
| <Older 6351-6360 Newer> Return to current articles. |
